Blood cancers

Shelved cancer drug given second chance in relapsed/refractory ALL

An older BCL-2 inhibitor has been pulled off the shelf and tested in combination with venetoclax for patients with relapsed/refractory ALL. Navitoclax, which is also a BCL-XL and BCL-W inhibitor, was shelved in the past due its primary toxicity of severe thrombocytopenia. However the advent of the highly selective BCL-2 inhibitor venetoclax provided an opportunity ...

Already a member?

Login to keep reading.

© 2021 the limbic